Current Events > World's first ever Ebola vaccine gets approved for global usage

(+) Yeah! (+)

The world finally has its first ever approved Ebola vaccine.

Within 48 hours of the European Commission approving the vaccine earlier this week, the World Health Alliance (WHO) verified that the treatment also reached its health and safety standards for global use, making it the first vaccine with clinical efficacy to protect individuals 18 years of age or older at risk of infection with the Ebola virus.

The Ervebo vaccine, which was developed by pharmaceutical company Merck, has already been used to quell emergency outbreaks in the Democratic Republic of the Congo (DRC) and several other neighboring countries.

Data from clinical trials and compassionate use protocols have shown that Ervebo protects against Ebola virus disease in humans following a single-dose administration. The vaccine is being used under compassionate use to protect people, including children and pregnant women, at highest risk of infection as part of a ring vaccination strategy, as well as a targeted geographical vaccination when ring vaccination is not feasible. As of this week, more than 250,000 people have been vaccinated in DRC, as well as in Burundi, Uganda, South Sudan, Guinea, and Rwanda.

This is a vaccine with huge potential, said Dr Seth Berkley, CEO of Gavi the Vaccine Alliance. It has already been used to protect more than 250,000 people in the DRC and could well make major Ebola outbreaks a thing of the past.

At its next meeting in December 2019, the Gavi Board is set to make a decision on a long-term Gavi Ebola vaccine program that would include the creation of a global Ebola vaccine stockpile. This stockpile, contingent on the availability of WHOs prequalified vaccines and SAGE recommendations for their use, will enable countries to access and rapidly deploy Ebola vaccines in response to outbreaks. On top of the stockpile, the Board will also consider, if recommended, future support for preventive vaccination of high-risk groups outside of an outbreak such as healthcare workers in countries classified as being at high risk.

The current stockpile of Ebola investigational vaccine is available in part thanks to an agreement between Gavi and the vaccines manufacturer, Merck.

In return, the manufacturer was required to commit to submit an emergency use authorization application to WHO as well as an application for licensure to a stringent health authority and ensure the availability of an emergency stockpile of 300,000 investigational doses in the event of an outbreak occurring before licensure through a donation from the manufacturer to WHO. In January 2016, an Advance Purchase Commitment between Merck and Gavi was signed, creating the stockpile of investigational doses that is being used in DRC and neighbouring countries today.

In addition to its work making the investigational vaccine stockpile available, Gavi has provided $ 15.1 million to WHO to cover operational costs for the vaccination effort, funding vaccination teams, transportation, syringes and other vaccine supplies, as well as the ultra-cold fridges which keep the vaccine at the minus 60-80C temperatures it needs to remain effective. This also includes $ 2 million provided to fund vaccinations in neighboring countries Uganda, South Sudan, Burundi and Rwanda

Merck CEO Kenneth C. Frazier is now hailing the vaccines approval as a historic milestone and a testament to the power of science, innovation and public-private partnership. After recognizing the need and urgency for an Ebola vaccine, many came together across sectors to answer the global call for outbreak preparedness,'

Full Article: https://www.goodnewsnetwork.org/worlds-first-ebola-vaccine-approved-for-global-use/
https://i.imgur.com/UDTTeRI.jpg

Whoop whoop! Go science. Let's kick Ebola's butt like we did Polio!
---

Weeeeeeeew!
---

Zack_Attackv1 posted...

Weeeeeeeew!

yeah boi
---

Not if the antivaxxers have anything to say about it.

No one cares what they think, though.

---

It's about time.
---

Very good.
---

orangefire25 posted...

Very good.

Yes
---